Condition: Metastatic Pancreatic Cancer · Sponsor: Hutchmed
To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
This description comes directly from the study's public registry record.
Panfeng Tan · +86 21 20671828 · panfengt@hutch-med.com
Always discuss trial participation with your own doctor first.
| Nanjing Tianyinshan Hospital | Nanjing, Jiangsu, China | Not Yet Recruiting |
| Tianjin Cancer Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06361888